4D Pharma PLC (DDDD) 2018年年度报告「LSE」.pdf

1、4D pharma plc Annual Report and Accounts 2018Transforming how diseases are treated4D pharma plc Annual Report and Accounts 2018We are pioneers in harnessing bacteria as a novel and revolutionaryclass of medicines:LiveBiotherapeuticsWhat we doWe understand that bacteria in the human intestine known a

2、s thegut microbiome have an important function in many diseases.Importantly,we understand how they function and how they couldbe used as a revolutionary new class of medicines known asLiveBiotherapeutics.Our deep understanding of bacterial functionality enables us to develop Live Biotherapeutics for

3、 a large number of diseases including cancer,gastrointestinal disease,respiratory disease andcentral nervous system(“CNS”)disease.What sets us apart We are targeting a new,safer approach to drug development We are a fully integrated microbiome company with the capability to progress from research to

4、 production to clinic We have a well established manufacturing facility capable ofproducing products for clinical trial supply and beyond We understand mechanism:how our products exert their therapeutic effects and act asadrug We have developed and wholly own the largest intellectual property estate

5、 in the fieldLEARN MORE ABOUT WHAT WE DOPages 2 to 4STAY UP TO DATE ON OUR WEBSITEFOLLOW US ONLinkedInStrategicGovernanceFinancial4D pharma plc Annual Report and Accounts HighlightsFinancial highlights*Basic and diluted.Adjusted loss per share excludes non-recurring costs(see note 9).Cash,cash equiv

6、alents andcash on deposit(m)26.2m26.250.068.8181716Adjusted loss per share*(pence)36.17p36.1726.0815.21181716Total comprehensive lossaftertax(m)24.3m24.319.410.3181716Expenditure on research anddevelopment(m)24.9m24.916.910.2181716Total equity(m)45.8m45.869.886.5181716Operational highlights Collabor